Confirming disease pathology with biomarkers
Biomarkers can be used to help establish the underlying etiology of the clinical syndrome.
Biomarker tests that may detect cognitive issues help support the early detection of MCI due to AD by confirming abnormal pathophysiological changes related to Alzheimer’s disease.
The diagnostic value of AD as the cause of MCI provides the clinician an opportunity to intervene before greater neuronal damage occurs, and more cognition and function are lost.
Biomarker and Cognitive tests include:
- Heart Rate Variability Testing (1-2)
- Neurocognitive Testing
- Neuropsychological Testing
- Positron emission tomography (PET) imaging
- Cerebrospinal fluid (CSF) test
1 Heart Rate Variability and Cognitive Function: A Systematic Review “Frontiers in Neuroscience” July 9th, 2019 Autonomic Neuroscience.
Giuseppe Forte1*, Francesca Favieri1 and Maria Casagrande2*1Dipartimento di Psicologia, Sapienza Università di Roma, Rome, Italy. 2Dipartimento di Psicologia Dinamica e Clinica, Sapienza Università di Roma, Rome, Italy
2 Editorial: Integrity of the Autonomic Nervous System in Psychiatric and Neurological Disorders “Frontiers in Neuroscience” February 25, 2020 Autonomic Neuroscience.
Timo Siepmann, Ben Min-Woo Illigens and Kristian Barlinn Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, 2 Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States